Focused On-demand Library for OTU domain-containing protein 7B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q6GQQ9

UPID:

OTU7B_HUMAN

Alternative names:

Cellular zinc finger anti-NF-kappa-B protein; Zinc finger A20 domain-containing protein 1; Zinc finger protein Cezanne

Alternative UPACC:

Q6GQQ9; B7Z643; D3DUZ8; Q5SZ60; Q8WWA7; Q9NQ53; Q9UFF4

Background:

OTU domain-containing protein 7B, also known as Cellular zinc finger anti-NF-kappa-B protein, plays a crucial role in regulating the non-canonical NF-kappa-B pathway. It mediates deubiquitination of TRAF3, maintaining the balance of B-cell responses and mucosal immunity. Additionally, it influences T cell receptor signaling through deubiquitination of ZAP70, impacting T cell homeostasis and cytokine production.

Therapeutic significance:

Understanding the role of OTU domain-containing protein 7B could open doors to potential therapeutic strategies. Its involvement in key immune pathways suggests its potential as a target in modulating immune responses.